cilostazol has been researched along with Liver Steatosis in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "All three antiplatelet drugs, namely aspirin, ticlopidine and cilostazol, significantly attenuated liver steatosis, inflammation and fibrosis in the CDAA diet group." | 3.74 | Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. ( Abe, Y; Endo, H; Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Kobayashi, N; Kubota, K; Nagashima, Y; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Wada, K; Yoneda, M, 2008) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease linked to insulin resistance, oxidative stress, and cytokine imbalance." | 1.56 | Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is an increasingly studied condition that can progress to end-stage liver disease." | 1.48 | Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK. ( Choi, Y; Kim, HY; Kwon, WY; Lee, MH; Lee, SY; Nam, TG; Oh, YJ; Suh, SH; Yoo, YH, 2018) |
| "Cilostazol treatment ameliorated lipid accumulation induced by palmitate, and this effect was diminished when ABCA1 or LRP1 was silenced by small interference RNA." | 1.42 | Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. ( Cha, BS; Jeon, BH; Kang, ES; Kim, SH; Lee, BW; Lee, HC; Lee, YH; Yun, MR, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Deen, RM | 1 |
| Heeba, GH | 1 |
| Abdel-Latif, RG | 1 |
| Khalifa, MMA | 1 |
| Oh, YJ | 1 |
| Kim, HY | 1 |
| Lee, MH | 1 |
| Suh, SH | 1 |
| Choi, Y | 1 |
| Nam, TG | 1 |
| Kwon, WY | 1 |
| Lee, SY | 1 |
| Yoo, YH | 1 |
| Jeon, BH | 1 |
| Lee, YH | 1 |
| Yun, MR | 1 |
| Kim, SH | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Fujita, K | 1 |
| Nozaki, Y | 1 |
| Wada, K | 1 |
| Yoneda, M | 1 |
| Endo, H | 1 |
| Takahashi, H | 1 |
| Iwasaki, T | 1 |
| Inamori, M | 1 |
| Abe, Y | 1 |
| Kobayashi, N | 1 |
| Kirikoshi, H | 1 |
| Kubota, K | 1 |
| Saito, S | 1 |
| Nagashima, Y | 1 |
| Nakajima, A | 1 |
4 other studies available for cilostazol and Liver Steatosis
| Article | Year |
|---|---|
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; I | 2020 |
Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cilostazol; Diet, High-Fat; Down-Regulatio | 2018 |
Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter 1; Cilostazol; Diet, High-Fat; Fatty Liver; Hep | 2015 |
Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Aspirin; Cholesterol; Choline Deficiency; Cilostazol; Dietary Fats; D | 2008 |